InMed Pharmaceuticals Reports Promising Preclinical Results for Alzheimer's Treatment
TL;DR
InMed Pharmaceuticals' INM-901 offers a competitive edge by targeting neuroinflammation independently of amyloid beta or tau pathology, potentially leading to breakthroughs in Alzheimer's treatment.
INM-901 works by significantly reducing pro-inflammatory cytokines and inflammasome markers in neuroinflammation models, demonstrating dose-dependent efficacy in preclinical studies for Alzheimer's disease.
INM-901's potential to treat neurodegenerative diseases like Alzheimer's could improve millions of lives, marking a significant step towards a healthier future for aging populations.
Discover how InMed's INM-901, targeting CB1/CB2 receptors and PPARs, shows promise in reducing neuroinflammation and improving cognition in preclinical studies.
Found this article helpful?
Share it with your network and spread the knowledge!
InMed Pharmaceuticals Inc. (NASDAQ: INM) has unveiled promising preclinical data for its drug candidate INM-901, demonstrating significant reductions in neuroinflammation, a key factor in Alzheimer's disease progression. The findings, which show a dose-dependent decrease in pro-inflammatory cytokines and inflammasome markers, suggest INM-901's potential as a novel treatment approach, independent of traditional amyloid beta or tau pathology targets.
The orally administered compound, targeting CB1/CB2 receptors and PPARs, has also shown improvements in cognition and behavior in long-term animal studies. This positions INM-901 as a potential breakthrough in addressing the high unmet medical needs in neurodegenerative diseases, with Alzheimer's disease as the lead indication for further development.
InMed Pharmaceuticals plans to advance INM-901 through additional preclinical and IND-enabling studies, marking a significant step forward in the quest for effective Alzheimer's treatments. The full details of the preclinical results can be found in the company's press release at https://ibn.fm/HBoFJ.
Curated from InvestorBrandNetwork (IBN)
